A STEP-BY-STEP APPROACH TO DESIGNING ACCURATE DOSING REGIMENS Casebook in Pharmacokinetics and Drug Dosing uses real-life cases to teach pharmacy students, pharmacists, and clinical pharmacists how to apply pharmacokinetics to formulate proper dosing regimens. In order to be as clinically relevant as possible, the book not only discusses drugs with readily available therapeutic serum levels, but places equal emphasis on high-alert agents with narrow therapeutic indexes. Each drug chapter is written by clinical pharmacists who have hands-on experience in drug dosing and includes an overview of the drug’s pharmacology, including: Indications Mec hanisms of action Toxicities Pharmacokinetics There is comprehensive review and discussion of each drug's bioavailability, volume of distribution, clearance, half-life, therapeutic drug level monitoring, drug interactions, dosing, and availability. Each chapter is enhanced by numerous patient cases with clear step-by-step answers and explanations. Calculations, equations, and dosing recommendations are provided for each case.

Publisher's Note: Products purchased from Third Party sellers are not guaranteed by the publisher for quality, authenticity, or access to any online entitlements included with the product.A STEP-BY-STEP APPROACH TO DESIGNING ACCURATE DOSING REGIMENS Casebook in Pharmacokinetics and Drug Dosing uses real-life cases to teach pharmacy students, pharmacists, and clinical pharmacists how to apply pharmacokinetics to formulate proper dosing regimens. In order to be as clinically relevant as possible, the book not only discusses drugs with readily available therapeutic serum levels, but places equal emphasis on high-alert agents with narrow therapeutic indexes. Each drug chapter is written by clinical pharmacists who have hands-on experience in drug dosing and includes an overview of the drug’s pharmacology, including: Indications Mec hanisms of action Toxicities Pharmacokinetics There is comprehensive review and discussion of each drug's bioavailability, volume of distribution, clearance, half-life, therapeutic drug level monitoring, drug interactions, dosing, and availability. Each chapter is enhanced by numerous patient cases with clear step-by-step answers and explanations. Calculations, equations, and dosing recommendations are provided for each case.

New sections on dosing strategies in all chapters. New chapter on sirolimus under the Immunosuppressants section. Essential information on drug dosing in special populations, including patients with renal and hepatic disease, obesity, and congestive heart failure. 30% of chapters extensively revised, others lightly updated

When a patient comes in with a suspected infectious disease, knowledge is power. Now this knowledge is simplified, comprehensive and easy to find. The Pharmacist's Guide to Antimicrobial Therapy and Stewardship puts all the necessary information in one place, including: Evaluating potentially infected patients Identifying the infection's suspected source and related organisms Comparing the range of anti-infectives Knowing the factors that impact treatment Developing an antimicrobial stewardship program A step-wise approach walks logically from overall key concepts to disease- and drug-specific information. Disease states are summarized for easy reference. Tables make it easy to evaluate recommended treatment options. In infectious disease management, when answers are seldom black and white, this guide helps pharmacists make confident decisions.

The most current, hands-on book in the field, Applied Clinical Pharmacokinetics The perfect textbook for pharmacy students learning the clinical application of pharmacokinetics, which is the mathematical tools for modifying doages. Students like that each chapter includes sample problems throughout the chapter, with a ton of practice problems at the end. Answers for the practice problems are in the back, but not detailed like the sample problems) *Changes in the 3/e includes: *All chapters updated and revised, as needed, including critical new references *Antibiotic individualization and monitoring sections increases use of pharmacodynamic parameters (Cmax/MIC, AUC24/MIC, Time above MIC) in addition to pharmacokinetic parameters to adjust dosages *Anticonvulsants section includes 5 new agents (Fosphenytoin, Lamotrigine, Levetiracetam, Oxcarbazepine, Eslicarbazepine) *Immunosuppressants section includes 1 new agent (Sirolimus), About the Book Text focuses on the latest standardized techniques and approaches to patient-specific dosing and provides up-to-date information on more recently moniotored drugs. Features Clear, useful coverage of drug dosing and drug monitoring Clear and concise summary of pharmacokinetic and pharmacodynamic concepts Practical help with calculations and equations Focus on the latest standardized techniques and approaches to patient-specific dosing Up-to-date information on more recently monitored drugs Essential information on drug dosing in special populations, including patients with renal and hepatic disease, obesity, and congestive heart failure All the information practitioners need on drug categories such as antibiotics, cardiovascular agents, anticonvulsants, and immunosuppressants Full coverage of drugs such as Aminoglycosides, Vancomycin, Digoxin, Phenytoin, Carbamazepine, Theophylline, Cyclosporine, Tacrolimus, and Lithium Student friendly approach to teaching pharmacokinetics--sample problems embedded into the text to allow for students to apply what they are learing. .

In the evolving practice of pharmacokinetics (PK), it is important to keep on top of the latest advances. John E. Murphy, a well-known leader in the field of clinical pharmacokinetics, has updated and expanded his widely-used textbook and reference. Clinical Pharmacokinetics, Sixth Edition includes the most current information, covering issues such as rational use of drug concentration measurements, changes in dosing obese patients, and considerations for a wider variety of drugs for special populations. There is also a new chapter focused on pharmacogenomics and its impact on pharmacokinetic parameters, as well as discussion of pharmacogenomics throughout the book. The new edition includes everything you need to know about pharmacokinetics today: Drugs, dosing, and therapeutic. Drug concentration measurements. New chapter on the impact of pharmacogenomics. Neonatal, pediatric, obese, and geriatric dosing. Dosing in renal disease and creatinine clearance estimation. Drugs sorted by family and as single drugs. Written in a straightforward style, with numerous charts and lists, the sixth edition makes complicated dosing and monitoring information easy to find and understand. Whether you are a student or practitioner, it is a resource you will turn to for reliable guidance throughout your pharmacy career.

Basic Clinical Pharmacokinetics was designed to simplify pharmacokinetics to help pharmacy students in clinical settings and busy practitioners understand and visualize basic principles. An easy-to-read, case-study format has made the text a favorite among students, clinical professors, and practitioners. Part I provides a basic review of pharmacokinetic principles, with extensive explanations, graphic illustrations, and detailed algorithms. Part II explains the clinical applications of these principles to problems commonly encountered in the practice setting with specific drugs. This edition includes the latest information on the clinical use of serum drug concentrations. New case studies and examples demonstrate the application of pharmacokinetics in today's clinical practice.

Essential Pharmacotherapy Data at Your Fingertips! A Doody's Core Title ESSENTIAL PURCHASE! 4 STAR DOODY'S REVIEW "The book addresses all aspects of 84 disease states and disorders, from presentation and pathology to treatment and monitoring. Each chapter focuses on individual groups of medication considered for treatment and gives a concise overview of them in easy to see bulleted points. The qualities that I find especially useful are that charts and algorithms are easily identifiable and tables are shaded light gray for quick reference . . . Although this handbook contains an enormous amount of information, it conveniently fits into a lab coat pocket. It is an extremely useful reference." -- Doody's Pharmacotherapy Handbook delivers the essential information you need to quickly and confidently make drug therapy decisions for eighty-four diseases and disorders. Featuring a convenient alphabetized presentation, the book utilizes text, tables, figures, and treatment algorithms to make important drug data readily accessible and easily understandable. Features: Consistent chapter organization that includes: Disease state definition, Concise review of relevant pathophysiology, Clinical presentation, Diagnosis, Desired outcome, Treatment, Monitoring Six valuable appendices, including a new one on the management of pharmacotherapy in the elderly NEW chapters on adrenal gland disorders and influenza The ideal companion to Pharmacology: A Pathophysiologic Approach, 7e by Joseph DiPiro et al.

The adulteration and fraudulent manufacture of medicines is an old problem, vastly aggravated by modern manufacturing and trade. In the last decade, impotent antimicrobial drugs have compromised the treatment of many deadly diseases in poor countries. More recently, negligent production at a Massachusetts compounding pharmacy sickened hundreds of Americans. While the national drugs regulatory authority (hereafter, the regulatory authority) is responsible for the safety of a country's drug supply, no single country can entirely guarantee this today. The once common use of the term counterfeit to describe any drug that is not what it claims to be is at the heart of the argument. In a narrow, legal sense a counterfeit drug is one that infringes on a registered trademark. The lay meaning is much broader, including any drug made with intentional deceit. Some generic drug companies and civil society groups object to calling bad medicines counterfeit, seeing it as the deliberate conflation of public health and intellectual property concerns. Countering the Problem of Falsified and Substandard Drugs accepts the narrow meaning of counterfeit, and, because the nuances of trademark infringement must be dealt with by courts, case by case, the report does not discuss the problem of counterfeit medicines.

This treatise had its origins in the authors' strong opinion that the discovery of new drugs, especially of innovative therapeutic agents, really does not happen as a spontaneous sequel to investiga tive research, no matter how penetrating such research may be. Rather, it seemed to us that the discovery of innovative therapeutic agents was a very active process, existing in and of itself, and demanding full attention-it was not simply a passive, dependent by-process of investigative research. And yet, many researchers some close confreres of the authors, others more distant-believed otherwise. We felt that their view reflected unrealistic thinking and that reality probably lay closer to what Beyer" maintained: We are taught to believe that if we can understand a disease it should be easy enough to figure out, say, the molecular configuration of a definitive receptor mechanism somewhere along the line and to design a specific drug . . . . And so we start out to understand the disease but never get around to doing much about therapy. The authors very soon realized that there was essentially no quantitive information available on just where and how innovative therapeutic agents were discovered. There were only anecdotal accounts, and these were able to be selected and presented in ways that could be used to defend any point of view.